Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Recruiting Phase 1 Interventional Study
Hematologic Malignancy GvHD GVHD,Acute GVHD, Chronic Hematopoietic Stem Cell Transplant Acute Lymphoblastic Leukemia, Adult B-Cell Acute Lymphoblastic Leukemia, Adult T-Cell Acute Myeloid Leukemia in Remission Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia, in Remission Cancer Remission
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Prevention
Participants needed
36 (estimated)
Sponsor
Tr1X, Inc. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML) 2. Males and Females Age ≥ 18 years. 3. Weight of ≥ 35 Kg. 4. Ka…
Contacts

Tr1X Clinical Trials

858-283-7879

Tr1xClinicalTrials@Tr1x.bio

CONTACT